A guided discovery tool for identifying current demand, referred-out opportunities, treatment-capability gaps, and the potential business value of a multi-application platform.
Quick context, captured as you talk. Not required for the math below.
"What are you treating today, and how many patients last month?" Sessions per patient matters, don't assume it's one.
| Current treatment | Typical Patients/mo | Sessions/pt | Avg $/Sess | Monthly revenue | Source |
|---|
Venus markets Versa Pro as a multi-application platform with 10 applicators, 25 treatments, and support for 100+ aesthetic goals. The supplied public product page identifies these eight major treatment categories but does not individually itemize all 25 marketed treatments, so we are not inventing that list. Go through these together and mark each one based on what the doctor tells you, don't presume.
| Capability | Applicator / verified indication | Status | Typical Pts/mo | Sess/pt | Avg $/Sess | Source |
|---|
Auto-filled from anything marked "Interested in adding" above. No re-entry needed.
| Opportunity | Typical Pts/mo | Sess/pt | Avg $/Sess | Monthly revenue |
|---|
This is a simple two-stage ramp estimate, not a monthly adoption curve, and it does not change the headline steady-state payback figure below. Staff training curve and true per-applicator consumable cost beyond the variable-cost field aren't separately modeled.
| Conservative (70%) | Target (100%) | Growth (130%) | |
|---|---|---|---|
| Total monthly revenue (current + expansion) | — | — | — |
| Payback (months, expansion-only) | — | — | — |
Scenarios apply 70% / 100% / 130% to selected expansion economics only. Current revenue is shown for total-opportunity context but never shortens equipment payback.
Generated from the current assessment. Physician-facing, print-ready.
This summary reflects user-entered practice assumptions and calculated estimates, it is not a guaranteed clinical, financial, or business outcome. Equipment payback and break-even reflect selected expansion opportunities only and exclude current practice revenue. Indications, pricing, and regulatory status must be verified against current official Venus documentation before use.
Fill in the Practice Snapshot to generate this recap.
Enter current treatment activity in Step 1.
No growth opportunity selected yet.
No growth opportunity selected yet.
Official Venus Versa Pro product webpage, supplied PDF capture (venus.ai/venus-versa-pro). This source supports Venus's "10 applicators, 25 treatments, 100+ aesthetic goals" statement, the eight public treatment categories, the public TriBella description, and the supplied indications-for-use language below. The supplied public product page does not individually itemize all 25 marketed treatments.
Indications-for-use, exactly as supplied: Venus Versa™ is cleared by the FDA, licensed by Health Canada, and has CE Mark as a multi-application device for aesthetic and cosmetic procedures. SR515/SR580 are cleared/licensed/marked for benign pigmented epidermal and cutaneous lesions and benign cutaneous vascular lesions. HR650/650XL and HR690/690XL are cleared/licensed/marked for removal of unwanted hair and stable long-term or permanent hair reduction, Fitzpatrick I-IV. AC Dual is cleared/licensed/marked for treatment of acne vulgaris. DiamondPolar and OctiPolar are FDA-cleared for non-invasive treatment of moderate-to-severe facial wrinkles/rhytides in females, Fitzpatrick I-IV; DiamondPolar is additionally Health Canada licensed and CE marked for the same. OctiPolar is licensed by Health Canada and CE marked for temporary body contouring via skin tightening, circumferential reduction, and cellulite reduction, this is not the same as U.S. FDA clearance for that specific use, confirm current U.S. indications before customer use. NanoFractional RF (Viva) is cleared/licensed/marked for dermatological procedures requiring ablation and resurfacing of the skin.